EMAIL THIS PAGE TO A FRIEND

British journal of pharmacology

Methyl salicylate lactoside inhibits inflammatory response of fibroblast-like synoviocytes and joint destruction in collagen-induced arthritis in mice.


PMID 24712652

Abstract

Methyl salicylate 2-O-β-d-lactoside (MSL), whose chemical structure is similar to that of salicylic acid, is a natural product derivative isolated from a traditional Chinese herb. The aim of this study was to investigate the therapeutic effect of MSL in mice with collagen-induced arthritis (CIA) and explore its underlying mechanism. The anti-arthritic effects of MSL were evaluated on human rheumatoid fibroblast-like synoviocytes (FLS) in vitro and CIA in mice in vivo by obtaining clinical scores, measuring hind paw thickness and inflammatory cytokine levels, radiographic evaluations and histopathological assessments. Treatment with MSL after the onset of arthritis significantly prevented the progression and development of rheumatoid arthritis (RA) in CIA mice without megascopic gastric mucosa damage. In addition, MSL inhibited the production of pro-inflammatory mediators, the phosphorylation and translocation of NF-κB, and cell proliferation induced by TNF-α in FLS. MSL non-selectively inhibited the activity of COX in vitro, but was a more potent inhibitor of COX-2 than COX-1. MSL also inhibited the phosphorylation of inhibitor of NF-κB kinase, IκBα and p65, thus blocking the nuclear translocation of NF-κB in TNF-α-stimulated FLS. MSL exerts therapeutic effects on CIA mice, suppressing the inflammatory response and joint destruction by non-selectively inhibiting the activity of COX and suppressing activation of the NF-κB signalling pathway, but without damaging the gastric mucosa. Therefore, MSL has great potential to be developed into a novel therapeutic agent for the treatment of RA.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB1100404
Anti-RELA (51-65) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
SAB4300294
Anti-RELA (Ab-254) antibody produced in rabbit, affinity isolated antibody
SAB4300295
Anti-RELA (Ab-276) antibody produced in rabbit, affinity isolated antibody
SAB4300506
Anti-RELA (Ab-311) antibody produced in rabbit, affinity isolated antibody
SAB4300296
Anti-RELA (Ab-435) antibody produced in rabbit, affinity isolated antibody
SAB4300297
Anti-RELA (Ab-468) antibody produced in rabbit, affinity isolated antibody
SAB4300442
Anti-RELA (Ab-505) antibody produced in rabbit, affinity isolated antibody
SAB4300469
Anti-RELA (Ab-529) antibody produced in rabbit, affinity isolated antibody
SAB4300298
Anti-RELA (Ab-536) antibody produced in rabbit, affinity isolated antibody
AV100779
Anti-RELA antibody produced in rabbit, IgG fraction of antiserum
SAB2101980
Anti-RELA antibody produced in rabbit, affinity isolated antibody
SAB2103066
Anti-RELA antibody produced in rabbit, affinity isolated antibody
C0858 Cyclooxygenase 2 human, ≥70% (SDS-PAGE), recombinant, expressed in baculovirus infected Sf21 cells, aqueous solution, ≥8000 units/mg protein
SAB1404309
Monoclonal Anti-RELA antibody produced in mouse, clone 8G3, ascites fluid
SAB5300389
Monoclonal Anti-RELA antibody produced in mouse, clone 6H7, ascites fluid